POV: It’s Time to Regulate the Fertility Industry
By George Annas,
Boston University Today
| 07. 16. 2015
Untitled Document
The fertility industry is big business. There are more than 450 fertility clinics in the United States alone, and their assisted reproduction technology (ART) procedures result in about 50,000 live birth deliveries and 62,000 infants a year (some deliveries involve multiple babies). This is about 1.5 percent of all live births, but 5.7 percent of all low-birth-weight babies. Of ART babies, 36 percent are born prematurely (compared to 12 percent of non-ART babies). Multiple births can put both mother and babies at risk. Singletons account for about 55 percent of all ART infants, with 42 percent twins and 3 percent triplets or more. This compares to 97 percent of all non-ART births that are singletons. This incredibly high incidence of multiple births and premature infants in ART is a problem that has yet to be effectively addressed, although transferring single embryos seems likely to be the primary solution.
The fertility industry responds to a real need and helps many couples have children they could not otherwise have. Nonetheless, because of the intense desire on the part of patients...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Patrick Foong, BioNews | 11.03.2025
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...